Loading
Pembrolizumab shrank tumours in about a third of patients with recurrent or metastatic cutaneous squamous cell carcinoma, with most responses lasting beyond a year, leading to its approval as an alternative to cemiplimab.
Phase 2 study of 105 patients with recurrent or metastatic cutaneous squamous cell carcinoma, most previously treated, given pembrolizumab every three weeks.
Objective response was 34.3 percent with complete response in 3.8 percent, median duration of response not reached, median progression-free survival 6.9 months, and toxicity typical of PD-1 blockade; a later cohort in locally advanced disease responded in about half.
Pembrolizumab is an approved first-line option for advanced cutaneous squamous cell carcinoma alongside cemiplimab.
Shares Jean-Jacques Grob, Advanced cutaneous squamous cell carcinoma.
Shares Advanced cutaneous squamous cell carcinoma, Pembrolizumab.
Shares KEYNOTE-629, Advanced cutaneous squamous cell carcinoma.
Shares KEYNOTE-629, Advanced cutaneous squamous cell carcinoma.
Shares KEYNOTE-629, Advanced cutaneous squamous cell carcinoma.
Shares KEYNOTE-629, Advanced cutaneous squamous cell carcinoma.